94
Participants
Start Date
October 1, 2025
Primary Completion Date
September 30, 2027
Study Completion Date
September 30, 2030
Tislelizumab
200 mg on Day 1 every 3 weeks and repeat for 2 or 4 cycles. The incidence of adverse events with Tislelizumab is relatively low. The Tislelizumab dose adjustment was implemented according to the prescribing information.
Oxaliplatin
Oxaliplatin 130mg/m2 on Day 1 every 3 weeks and repeat for 2 or 4 cycles. The dose reduction protocol for oxaliplatin-induced toxicity was implemented according to the study in British Journal of Cancer (2018) 118:1322-1328.
Capecitabine
Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy from Day 1 to Day 14 every 3 weeks and repeat for 2 or 4 cycles. The dose reduction protocol for capecitabine-induced toxicity was implemented according to the study in British Journal of Cancer (2018) 118:1322-1328.
The First Affiliated Hospital of Guangxi Medical University, Nanning
The First Affiliated Hospital of Xiamen University
OTHER
The First Affiliated Hospital of University of South China
OTHER
First Affiliated Hospital of Guangxi Medical University
OTHER